Merck Join Forces with Hansoh Pharma to Develop HS-10535
Shots:
- Merck and Hansoh Pharma have signed an exclusive worldwide licensing agreement for the development of HS-10535
- As per the agreement, Merck secures exclusive rights for developing, manufacturing and commercializing HS-10535 in exchange for $112M upfront, up to $1.9B development, regulatory & commercial milestones plus royalties. Hansoh will co-promote & exclusively commercialize HS-10535 in China
- HS-10535 (oral) is a small molecule GLP-1 receptor agonist that is currently being evaluated under preclinical studies
Ref: Merck | Image: Merck & Hansoh Pharma
Related News:- Merck Discontinues Clinical Development Programs Evaluating Vibostolimab and Favezelimab for Various Indications
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
